Search results
Showing 646 to 660 of 2026 results for nice guidelines
{"@type":"ListItem","position":3,"item":{"name":"Podcasts"}}]} Podcasts Our NICE talks podcasts bring you the real life experiences of...
This guideline covers supporting the social and emotional wellbeing of vulnerable children under 5 through home visiting, childcare and early education. It aims to optimise care for young children who need extra support because they have or are at risk of social or emotional problems.
This guideline covers contraceptive services for under-25s. It aims to ensure all under-25s are given advice and information on all types of contraception. This includes additional tailored support to meet the particular needs and choices of those who are socially disadvantaged or who may find it difficult to use these services.
View recommendations for PH51Show all sections
Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)
Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
Management of vomiting in children and young people with gastroenteritis: ondansetron (ESUOM34)
Summary of the evidence on ondansetron for the management of vomiting in children and young people with acute gastroenteritis
How you can use our recommendations, tools and resources: cardiovascular disease
How to use NICE guidance to reduce health inequalities in people experiencing cardiovascular disease (CVD).
This indicator covers patient experiences of dental services. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
In virtual wards, patients remain at home to receive hospital-level care. Our guidance can help you determine if patients are suitable for admission to the virtual wards system.
Get expert advice and support from NICE International, part of the UK's National Institute for Health and Care Excellence, for a project in your country
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)
Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
Myocardial infarction: medication for MI in preceding 12 months (IND125)
This indicator covers the percentage of patients who had a myocardial infarction in the preceding 1 April to 31 March and who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), dual antiplatelet therapy, a statin and a beta blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM79
Padeliporfin for untreated localised prostate cancer (TA546)
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.